Marianna Herrera, BSN, RN, IgCN
Clinical Nurse Educator
Marianna Herrera, BSN, RN, IgCN is a Clinical Nurse Educator at Nufactor Specialty Pharmacy. Marianna has over 25 years of infusion therapy experience, specializing in immunoglobulin therapy and a wide range of biologic, monoclonal antibody, and specialty medications. She earned her Bachelor of Nursing degree from the University of Texas at El Paso. Marianna is a member of Immunoglobulin National Society (IgNS) and Texas Association of Nurse Anesthetists. An Immunoglobulin Certified Nurse (IgCN), Marianna empowers clinicians through training nurses and home health agencies on the administration of Nufactor’s therapies and providing continuing education on immune globulin and infliximab therapies. Marianna also supports and educates patients and caregivers on their disease states and possible adverse events, ensuring patients feel supported throughout their treatment journey.
Marianna's Recent Posts
Anaphylaxis Protocols in Home Infusions: Safety Guidelines for Nurses
Home infusion nursing brings the unique responsibility of providing high-quality care outside the traditional clinical environment. In the home setting nurses are a “One Man Team”, unlike the hospitals that provide rapid response teams at a push of a button. While serious adverse drug reactions (ADRs) are rare, anaphylaxis can occur suddenly and without warning, requiring immediate recognition and decisive action. Nufactor patients are staffed with nurses who must undergo vetting and skills assessment prior to providing care to patients. This is done to ensure they are fully prepared to not only safely and effectively complete the infusion but also recognize any adverse drug reactions and be prepared to intervene accordingly.
Managing Infusion Side Effects – Who to Call and When
Timely recognition and communication of side effects during IVIg or SCIG therapy is essential to patient safety and treatment adherence. Reactions vary by patient and can range from mild to severe. As the nurse, you are often the only clinician physically present during infusions—your assessments and communication are critical in managing the patient’s care. If side effects are not managed appropriately and tolerability becomes an issue, the patient may want to stop therapy, which could impact the management of their condition. The following is a guide to help you determine who to call and when.
HYQVIA® 10% — Learn About Expanded FDA-Approval for Treating PIDD and CIDP
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration was first FDA-approved in 2014 for primary immunodeficiency (PIDD) in adults.
Mastering IV Access at Home: Best Practices for Safe Infusion Therapy
Strong competency in both peripheral and central access devices is imperative in ensuring patient safety and optimal outcomes.
Understanding Crohn’s Disease: Symptoms, Diagnosis, and Treatment Options
Crohn’s disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the gastrointestinal (GI) tract.
Living with Chronic Lymphocytic Leukemia (CLL): Understanding the Journey, Symptoms, and Treatment Options
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults in Western countries. CLL is a disease of the white blood cells that typically affects adults over the age of 50 and is rarely seen in children.
